[go: up one dir, main page]

ZA200007321B - Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src. - Google Patents

Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src.

Info

Publication number
ZA200007321B
ZA200007321B ZA200007321A ZA200007321A ZA200007321B ZA 200007321 B ZA200007321 B ZA 200007321B ZA 200007321 A ZA200007321 A ZA 200007321A ZA 200007321 A ZA200007321 A ZA 200007321A ZA 200007321 B ZA200007321 B ZA 200007321B
Authority
ZA
South Africa
Prior art keywords
angiogenesis
methods
src protein
nucleic acids
modulation
Prior art date
Application number
ZA200007321A
Other languages
English (en)
Inventor
David A Cheresh
Pamela L Schwartzberg
Brian Eliceiri
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of ZA200007321B publication Critical patent/ZA200007321B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
ZA200007321A 1998-05-29 2000-12-08 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src. ZA200007321B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8722098P 1998-05-29 1998-05-29

Publications (1)

Publication Number Publication Date
ZA200007321B true ZA200007321B (en) 2002-03-08

Family

ID=22203825

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200007321A ZA200007321B (en) 1998-05-29 2000-12-08 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src.

Country Status (23)

Country Link
US (1) US7585841B2 (es)
EP (1) EP1082415B1 (es)
JP (1) JP4806487B2 (es)
KR (1) KR20010085261A (es)
CN (1) CN1304567C (es)
AT (1) ATE506073T1 (es)
AU (1) AU762955C (es)
BR (1) BR9910787A (es)
CA (1) CA2330025C (es)
CZ (1) CZ302918B6 (es)
DE (1) DE69943374D1 (es)
DK (1) DK1082415T3 (es)
ES (1) ES2361659T3 (es)
HU (1) HU227985B1 (es)
MX (1) MXPA00011821A (es)
NO (1) NO327610B1 (es)
PT (1) PT1082415E (es)
RU (1) RU2222342C2 (es)
SK (1) SK287330B6 (es)
TR (1) TR200100430T2 (es)
UA (1) UA75565C2 (es)
WO (1) WO1999061590A1 (es)
ZA (1) ZA200007321B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685938B1 (en) * 1998-05-29 2004-02-03 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
KR20010085261A (ko) * 1998-05-29 2001-09-07 빙검 더글라스 에이. 티로신 키나제 Ｓｒｃ를 사용하는, 맥관형성의 조절에유용한 방법 및 조성물
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
RU2271216C2 (ru) * 1999-12-22 2006-03-10 Дзе Скриппс Рисерч Инститьют Модуляторы ангиогенеза и проницаемости сосудов
US7485414B2 (en) 2002-08-30 2009-02-03 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
CN103463621B (zh) * 2006-10-31 2016-01-06 托莱多大学 Src和Src家族激酶的Na+/K+-ATP酶特异性肽抑制剂/激活剂
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
WO2010105172A1 (en) 2009-03-13 2010-09-16 Abraxis Bioscience, Llc Combination therapy with thiocolchicine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7432496A (en) * 1995-10-13 1998-05-11 Regents Of The University Of Minnesota Consolidated ligands with increased affinities and methods of use thereof
US6335010B1 (en) * 1996-11-08 2002-01-01 University Of California At San Diego Gene therapy in coronary angioplasty and bypass
KR20010085261A (ko) * 1998-05-29 2001-09-07 빙검 더글라스 에이. 티로신 키나제 Ｓｒｃ를 사용하는, 맥관형성의 조절에유용한 방법 및 조성물
GB2341182A (en) * 1998-09-01 2000-03-08 Yamanouchi Uk Ltd Protein comprising amino acid sequences having SH3 domain binding activity and nuclear localisation activity

Also Published As

Publication number Publication date
US20060009412A1 (en) 2006-01-12
EP1082415A4 (en) 2003-07-09
KR20010085261A (ko) 2001-09-07
RU2222342C2 (ru) 2004-01-27
EP1082415B1 (en) 2011-04-20
CA2330025A1 (en) 1999-12-02
EP1082415A1 (en) 2001-03-14
AU762955C (en) 2005-03-24
JP2002516344A (ja) 2002-06-04
CA2330025C (en) 2009-03-17
TR200100430T2 (tr) 2002-05-21
HK1041289A1 (en) 2002-07-05
CZ302918B6 (cs) 2012-01-18
UA75565C2 (uk) 2006-05-15
DK1082415T3 (da) 2011-06-14
US7585841B2 (en) 2009-09-08
SK287330B6 (sk) 2010-07-07
SK18112000A3 (sk) 2001-09-11
NO20006026D0 (no) 2000-11-28
NO20006026L (no) 2001-01-24
ES2361659T3 (es) 2011-06-21
BR9910787A (pt) 2001-10-30
CN1319131A (zh) 2001-10-24
ATE506073T1 (de) 2011-05-15
DE69943374D1 (de) 2011-06-01
AU762955B2 (en) 2003-07-10
NO327610B1 (no) 2009-08-31
HUP0102614A2 (hu) 2001-11-28
HU227985B1 (en) 2012-07-30
WO1999061590A9 (en) 2000-03-09
HUP0102614A3 (en) 2005-11-28
WO1999061590A1 (en) 1999-12-02
PT1082415E (pt) 2011-07-04
MXPA00011821A (es) 2004-07-30
CN1304567C (zh) 2007-03-14
AU4101399A (en) 1999-12-13
JP4806487B2 (ja) 2011-11-02
CZ20004435A3 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
DE69828408D1 (de) Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
AU2464601A (en) Tricyclic protein kinase inhibitors
IL125735A (en) Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound
MX9709442A (es) Metodo y composiciones para la inhibicion de interacciones entre proteina adaptadora y tirosinquinasa.
WO1997045137A8 (en) Methods and compositions useful for inhibition of angiogenesis
BR0010220A (pt) Compostos de pirimidinona
AU2002228912A1 (en) Short peptides from the "a-region" of protein kinases which selectively modulate protein kinase activity
AU762955C (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
PL356815A1 (en) Angiogenesis and vascular permeability modulators and inhibitors
WO2002046384A3 (en) Kinases and phosphatases sequences, and use thereof
WO1999049038A3 (en) Human calcium-binding proteins
MXPA02010759A (es) Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AU2001289034A1 (en) Novel pdes and uses thereof
WO1999031128A3 (en) Human tumor necrosis factor-r2-like proteins
BR0013228A (pt) Método e composições utilizados para modulação de angiogenese usando proteìna quinase raf e ras
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
WO2002088358A3 (en) Human fibroblast growth factor-related compositions
IL151211A0 (en) Compositions useful for regulating parkin gene activity
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
WO1999043832A3 (en) Human proteinase molecules